Comparative Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Reducing Intraocular Pressure in Patients with Primary Open-Angle Glaucoma

Background: Glaucoma is a progressive optic neuropathy in which increased intraocular pressure (IOP) is a primary risk factor, leading to vision loss. The present study was initiated to compare the intraocular pressure (IOP)-lowering efficacy of 0.03% bimatoprost and 0.004% travoprost in patients with unilateral primary open-angle glaucoma (POAG). Methods and Results: A total of 100 patients with POAG were treated with a single hypotensive agent during a 6-month follow-up period. The patients were divided into two groups. Group 1 patients (n=50) were treated with 0.03% bimatoprost, and Group 2 patients (n=50) were treated with 0.004% travoprost. We assessed the IOP at baseline, 1 week, 4 weeks, 12 weeks, and 6 months after treatment. There were no significant differences between the two treatments at the initial stage. At 1 week and 4 weeks after treatment, the mean IOP significantly decreased from baseline in both groups. There were no significant differences between the two treatments at these stages. After 12 weeks of treatment, IOP continued to decrease effectively in both groups; however, 0.03% bimatoprost provided lower IOP values, and there was a significant difference between groups. In the bimatoprost group, compared to baseline, the reduction was 30.9%, while in the travoprost group, the reduction was 28.3% (P=0.043). The difference was greater after 6 months: in the bimatoprost group, the reduction was 33.0% compared to baseline, while in the travoprost group, the reduction was 29.7% (P=0.033). Conclusion: The consistently lower IOP values for 0.03% bimatoprost treatment suggest it may be more effective in lowering IOP than 0.004% travoprost.